Novabay(NBY)发布Q3财报，2024财年前三财季累计收入747.20万美元，去年同期累计收入为835.40万美元，同比减少10.56%。 2024财年前三财季累计净亏损601.10万美元，去年同期累计净亏损为553.20万美元，同比扩大8.66%。 本财年累计基本每股收益为-3.97美元，去年同期为-79.58美元。 公司所属行业为制药。 Novabay Pharmaceuticals, ...

NovaBay (NYSE:NBY) said it has accepted a revised offer from PRN Physician Recommended Nutriceuticals that increases the base purchase price of its Avenova eyecare business to $11.5M from $9.5M. In ...

NovaBay Pharmaceuticals (NYSE:NBY) announced on Tuesday that it has received an unsolicited, non-binding offer from Refresh ...

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh ...

NovaBay (NBY) announced that the company’s board of directors has determined that an unsolicited and non-binding offer from Refresh ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...